Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM.

Oncologist. 2019 Oct 18. pii: theoncologist.2019-0356. doi: 10.1634/theoncologist.2019-0356. [Epub ahead of print]

PMID:
31628267
2.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Seibold M, Stühmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, Holzgrabe U, Brünnert D, Barrio S, Kortüm KM, Solimando AG, Chatterjee M, Einsele H, Rosenwald A, Bargou RC, Steinbrunn T.

Haematologica. 2019 Oct 10. pii: haematol.2019.223024. doi: 10.3324/haematol.2019.223024. [Epub ahead of print]

3.

IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.

Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Viá M, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM.

Haematologica. 2019 Sep 26. pii: haematol.2019.217943. doi: 10.3324/haematol.2019.217943. [Epub ahead of print]

4.

MYC dysregulation in the progression of multiple myeloma.

Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ; MMRF CoMMpass Network, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.

Leukemia. 2019 Aug 22. doi: 10.1038/s41375-019-0543-4. [Epub ahead of print] No abstract available.

PMID:
31439946
5.

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.

Munawar U, Rasche L, Müller N, Vogt C, Da-Via M, Haertle L, Arampatzi P, Dietrich S, Roth M, Garitano-Trojaola A, Steinhardt MJ, Strifler S, Gallardo M, Martinez-Lopez J, Bargou RC, Heckel T, Einsele H, Stühmer T, Kortüm KM, Barrio S.

Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24. No abstract available.

PMID:
31340981
6.

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H.

J Clin Med. 2019 Jul 9;8(7). pii: E997. doi: 10.3390/jcm8070997. Review.

7.

Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.

Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kortüm KM.

Leuk Lymphoma. 2019 Jul 18:1-4. doi: 10.1080/10428194.2019.1636981. [Epub ahead of print] No abstract available.

PMID:
31317812
8.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Aug;44(8):620-624. doi: 10.1097/RLU.0000000000002638.

PMID:
31274607
9.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002638. [Epub ahead of print]

PMID:
31205144
10.

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.

Rasche L, Kortüm KM, Raab MS, Weinhold N.

Int J Mol Sci. 2019 Mar 12;20(5). pii: E1248. doi: 10.3390/ijms20051248. Review.

11.

Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.

Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kortüm KM, Störk S, Buck AK, Reiter T, Bauer WR, Lapa C.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1407-1416. doi: 10.1007/s00259-019-04290-y. Epub 2019 Feb 23.

PMID:
30798427
12.

[Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].

Kortüm KM, Einsele H.

Internist (Berl). 2019 Jan;60(1):34-41. doi: 10.1007/s00108-018-0528-9. Review. German.

PMID:
30536028
13.

Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma.

Kircher S, Stolzenburg A, Kortüm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C.

J Nucl Med. 2019 Mar;60(3):348-352. doi: 10.2967/jnumed.118.217539. Epub 2018 Nov 2.

PMID:
30389821
14.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31. Review.

15.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.

PMID:
30033832
16.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.

PMID:
30026573
17.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

18.

Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma.

Barrio S, DáVia M, Bruins L, Stühmer T, Steinbrunn T, Bittrich M, Einsele H, Stewart AK, Braggio E, Kortüm KM.

Methods Mol Biol. 2018;1792:117-128. doi: 10.1007/978-1-4939-7865-6_8.

PMID:
29797255
19.

Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.

Lapa C, Lückerath K, Kircher S, Hänscheid H, Grigoleit GU, Rosenwald A, Stolzenburg A, Kropf S, Einsele H, Wester HJ, Buck AK, Kortüm KM, Schirbel A.

Br J Haematol. 2019 Feb;184(3):440-443. doi: 10.1111/bjh.15096. Epub 2018 Jan 24. No abstract available.

PMID:
29363736
20.

First targeted therapy in multiple myeloma.

Kortüm KM, Einsele H.

Blood. 2017 Nov 30;130(22):2359-2360. doi: 10.1182/blood-2017-09-805341. No abstract available.

PMID:
29191974
21.

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Shi CX, Kortüm KM, Zhu YX, Bruins LA, Jedlowski P, Votruba PG, Luo M, Stewart RA, Ahmann J, Braggio E, Stewart AK.

Mol Cancer Ther. 2017 Dec;16(12):2862-2870. doi: 10.1158/1535-7163.MCT-17-0130. Epub 2017 Sep 27.

22.

11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.

Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM.

Theranostics. 2017 Jul 23;7(11):2956-2964. doi: 10.7150/thno.20491. eCollection 2017.

23.

Loss of FAM46C Promotes Cell Survival in Myeloma.

Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortüm KM, Luo M, Ahmann JM, Braggio E, Stewart AK.

Cancer Res. 2017 Aug 15;77(16):4317-4327. doi: 10.1158/0008-5472.CAN-16-3011. Epub 2017 Jun 15.

24.

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.

Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM.

Theranostics. 2017 Apr 8;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017.

25.

[11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions.

Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S.

Br J Haematol. 2018 Jun;181(5):701-703. doi: 10.1111/bjh.14696. Epub 2017 May 3. No abstract available.

PMID:
28466502
26.

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma.

Lapa C, Schirbel A, Samnick S, Lückerath K, Kortüm KM, Knop S, Wester HJ, Buck AK, Schreder M.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1097-1098. doi: 10.1007/s00259-017-3656-x. Epub 2017 Feb 25. No abstract available.

PMID:
28238021
27.

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.

Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerath K.

Theranostics. 2017 Jan 1;7(1):205-212. doi: 10.7150/thno.16576. eCollection 2017.

28.

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortüm KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E.

Leukemia. 2017 Jan;31(1):170-176. doi: 10.1038/leu.2016.172. Epub 2016 Jun 14.

29.

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS.

Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.

30.

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Rosenthal A, Luthi J, Belohlavek M, Kortüm KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK.

Blood Cancer J. 2016 Jan 15;6:e384. doi: 10.1038/bcj.2015.112.

31.

SnapShot: Multiple Myeloma.

Braggio E, Kortüm KM, Stewart AK.

Cancer Cell. 2015 Nov 9;28(5):678-678.e1. doi: 10.1016/j.ccell.2015.10.014.

32.

Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.

Shi CX, Kortüm KM, Zhu YX, Jedlowski P, Bruins L, Braggio E, Stewart AK.

Haematologica. 2015 Aug;100(8):e315-7. doi: 10.3324/haematol.2015.124297. Epub 2015 May 14. No abstract available.

33.

Cereblon binding molecules in multiple myeloma.

Kortüm KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK.

Blood Rev. 2015 Sep;29(5):329-34. doi: 10.1016/j.blre.2015.03.003. Epub 2015 Mar 27. Review.

PMID:
25843596
34.

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).

Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Ann Hematol. 2015 Jul;94(7):1205-11. doi: 10.1007/s00277-015-2344-9. Epub 2015 Mar 7.

35.

Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.

Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E.

Br J Haematol. 2015 May;169(3):445-8. doi: 10.1111/bjh.13211. Epub 2014 Nov 10. No abstract available.

36.

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.

Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10.

37.

[Multiple myeloma].

Kortüm KM, Engelhardt M, Rasche L, Knop S, Einsele H.

Internist (Berl). 2013 Aug;54(8):963-77. doi: 10.1007/s00108-013-3336-2. German.

PMID:
23860514

Supplemental Content

Loading ...
Support Center